ALLO - Allogene Therapeutics Inc

ALLO - Allogene Therapeutics Inc

https://allogene.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Why Is Allogene Therapeutics ( ALLO ) Up 9.4% Since Last Earnings Report?

Zacks Commentary • 3 days ago • score: 0.31

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

Zacks Commentary • 1 week, 3 days ago • score: 0.02

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

Zacks Commentary • 1 month ago • score: 0.00

ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.

Allogene Q2 Cash Tops $300 Million

Motley Fool • 1 month ago • score: -0.01

Allogene Therapeutics ( NASDAQ:ALLO ) reported second-quarter 2025 results on August 13, 2025, highlighting $302.6 million in cash and investments as of the end of Q2 2025 with a projected cash runway into the second half of 2027 despite reporting a GAAP net loss of $50.9 million.

Allogene Narrows Loss in Fiscal Q2

Motley Fool • 1 month ago • score: 0.07

Allogene Therapeutics ( NASDAQ:ALLO ) , a biotechnology company developing off-the-shelf cell therapies for cancer and autoimmune diseases, reported its second quarter 2025 results on August 13, 2025. The release highlighted a smaller-than-expected GAAP net loss for Q2 2025. as the company ...

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - Allogene Therapeutics ( NASDAQ:ALLO )

Benzinga • 1 month, 1 week ago • score: 0.08

Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

GlobeNewswire • 1 month, 1 week ago • score: 0.09

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced that it will report the ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.

52W High

$3.78

52W Low

$0.86

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.36

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.04

EV/Revenue (<3 favorable)

3859.62

P/S (TTM) (<3 favorable)

11631.14

P/B (<3 favorable)

0.74

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

17.45%

Institutions (25–75% balanced)

74.09%

Shares Outstanding

221,881,000

Float

164,975,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-180,040,992

EPS (TTM)

-1.10

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.55%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Bearish momentum

Value

-0.0082

Previous

-0.0135

Trend

Rising

Signal Cross

No cross

As of

Sep. 11, 2025